Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 3 Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Effects of Once Daily Oral Doses of 75 mg Azimilide Dihydrochloride on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator

NCT01464476 is registered in ClinicalTrials.gov with Forest Laboratories as lead sponsor.

NCT NCT01464476
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01464476 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 3 Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Effects of Once Daily Oral Doses of 75 mg Azimilide Dihydrochloride on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator
Lead sponsor
Forest Laboratories
Phase
Phase 3
Overall status
Terminated
Start date
November 30, 2011
Completion date
June 30, 2013
Enrollment
240 (actual)
Sites
138

Conditions

As the registry lists them; a condition with its own page is linked.

arrhythmias, cardiac, cardiovascular diseases, heart diseases, implantable cardioverter defibrillator